• Users Online: 210
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2022  |  Volume : 34  |  Issue : 3  |  Page : 227-233

A comparative study of efficacy and safety of alcaftadine 0.25% versus olopatadine hydrochloride 0.2% in allergic conjunctivitis at a tertiary care hospital


1 Postgraduate, Department of Pharmacology, Bangalore Medical College and Research Institute, Bangalore, Karnataka, India
2 Dean cum Director and Professor, Department of Pharmacology, Bangalore Medical College and Research Institute, Bangalore, Karnataka, India
3 Assistant Professor, Department of Ophthalmology, RRMCH, Former Fellow in Cornea and Refractive Surgeries, Minto Ophthalmic Hospital, Regional Institute of Ophthalmology, BMCRI, Bangalore, Karnataka, India

Correspondence Address:
Dr. Sriya Sridhar
Assistant Professor, Department of Ophthalmology, RRMCH, Former Fellow in Cornea and Refractive Surgeries, Minto Ophthalmic Hospital, Regional Institute of Ophthalmology, BMCRI, Bangalore, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/kjo.kjo_185_21

Rights and Permissions

Background: Ocular itching is the hallmark symptom of allergic conjunctivitis, accompanied by tearing, conjunctival redness, eyelid swelling, and chemosis. Alcaftadine and olopatadine hydrochloride are classified as dual-acting antiallergic agents, used in the treatment of allergic conjunctivitis. Objective: The aim is to compare the efficacy and safety of alcaftadine 0.25% and olopatadine hydrochloride 0.2% eye drops among patients with allergic conjunctivitis. Settings and Design: Ophthalmology outpatient department at Minto Ophthalmic Hospital, Bangalore Medical College and Research Institute, Bengaluru; prospective, randomized, comparative study. Subjects and Methods: This study was conducted among 120 patients suffering from grade 3 Allergic conjunctivitis and efficacy measured in terms of proportion of patients achieving symptomatic relief of allergic ocular signs and symptoms from grade 3 to grade 0 from baseline to 2 weeks, using Total Ocular Symptoms Score (TOSS) and Conjunctival Hyperemia scale. Safety assessed by monitoring treatment-emergent adverse effects. Continuous data assessed by unpaired, paired t-test and repeated measures-ANOVA and categorical data by Chi-square test. P <0.05 was considered statistically significant, whereas < 0.001 as highly significant. Results: Greater proportion of patients achieved symptomatic relief in the Alcaftadine group (98.3%) compared to the olopatadine hydrochloride group (90%) at end of 2 weeks. A significant and faster reduction in TOSS score was observed from baseline to 2 weeks in alcaftadine treated group compared to the olopatadine hydrochloride group (P < 0.05). Adverse events reported were headache, burning sensation, and mild redness in both groups. Conclusion: Alcaftadine 0.25% demonstrated greater efficacy in reducing ocular signs and symptoms of allergic conjunctivitis from baseline to 2 weeks, compared to olopatadine hydrochloride 0.2% with minimal side-effects.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed182    
    Printed4    
    Emailed0    
    PDF Downloaded32    
    Comments [Add]    

Recommend this journal